Alpine Immune Sciences Inc ALPN:NASDAQ

Last Price$10.25NASDAQ Closing Price as of 3:02PM ET 6/01/23
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.29(2.91%)
Bid (Size)$10.21 (2)
Ask (Size)$10.29 (2)
Day Low / High$9.57 - 10.33
Volume125.8 K

View Biotechnology IndustryPeer Comparison as of 06/01/2023


Alpine Immune Sciences Inc ( NASDAQ )

Price: $10.25
Change: +0.29 (2.91%)
Volume: 125.8 K
3:02PM ET 6/01/2023

Stoke Therapeutics Inc ( NASDAQ )

Price: $11.25
Change: +0.05 (0.45%)
Volume: 68.7 K
3:01PM ET 6/01/2023

Voyager Therapeutics Inc ( NASDAQ )

Price: $11.52
Change: +0.13 (1.17%)
Volume: 307.8 K
3:01PM ET 6/01/2023

Fate Therapeutics Inc ( NASDAQ )

Price: $5.16
Change: +0.11 (2.18%)
Volume: 954.9 K
3:02PM ET 6/01/2023

AnaptysBio Inc ( NASDAQ )

Price: $18.84
Change: -0.26 (1.36%)
Volume: 78.8 K
3:01PM ET 6/01/2023

Read more news Recent News

Alpine Immune Sciences Q1 Loss Was Less Than Expected on Lower Expenses, Wedbush Says
4:48PM ET 5/12/2023 MT Newswires

Alpine Immune Sciences' (ALPN) Q1 loss per share was less than expected after operational expenditures were lower than anticipated, Wedbush said Friday in...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q1 Revenue $9.4M
4:15PM ET 5/11/2023 MT Newswires


Alpine Immune Sciences' Q4 Net Loss Narrows, Revenue Falls; Expects Cash Position to Fund Operations Through 2025
8:46AM ET 3/24/2023 MT Newswires

Alpine Immune Sciences (ALPN) reported a Q4 net loss late Thursday of $0.41 per diluted share, narrowing from a loss of $0.52 a year earlier. Analysts...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q4 Revenue $2.8M, vs. Street Est of $11M
4:07PM ET 3/23/2023 MT Newswires


Company Profile

Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
Address188 East Blaine Street
Seattle, Washington 98102
Number of Employees48
Recent SEC Filing05/11/2023424B5
Executive Chairman & Chief Executive OfficerMitchell H. Gold
President & Head-Research & DevelopmentStanford L. Peng
Finance DirectorThaedra Thullberry
Chief Financial Officer, Secretary & Senior VPJames Paul Rickey

Company Highlights

Price Open$9.90
Previous Close$9.96
52 Week Range$4.82 - 10.95
Market Capitalization$491.6 M
Shares Outstanding48.0 M
SectorHealth Technology
Next Earnings Announcement08/10/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.71
Beta vs. S&P 500N/A
Revenue$705.0 K
Net Profit Margin-245.92%
Return on Equity-40.29%

Analyst Ratings as of 01/19/2023

Consensus RecommendationConsensus Icon
Powered by Factset